ENDRA Life Sciences (NDRA) Total Non-Current Liabilities (2019 - 2026)
ENDRA Life Sciences (NDRA) posted quarterly Total Non-Current Liabilities of $815857.0 for Q1 2026, down 4.23% year-over-year from $851928.0 in Q1 2025, and down 3.19% quarter-over-quarter from $842721.0 in Q4 2025.
ENDRA Life Sciences (NDRA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Total Non-Current Liabilities for 8 consecutive years, with $815857.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 4.23% year-over-year to $815857.0; the TTM figure through Mar 2026 stood at $815857.0 (down 4.23% YoY), while the FY2025 annual figure was $842721.0, down 34.51% from the prior year.
- Total Non-Current Liabilities fell to $815857.0 in Q1 2026 per NDRA's latest filing, from $842721.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.3 million in Q4 2024 and bottomed at $98421.0 in Q2 2024.
- Historically, Total Non-Current Liabilities has averaged $628945.5 across 5 years, with a median of $786870.5 in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 47.51% — and 2025, when it soared 670.04%.
- ENDRA Life Sciences' Total Non-Current Liabilities stood at $365919.0 in 2022, then plunged by 47.51% to $192062.0 in 2023, then surged by 569.97% to $1.3 million in 2024, then sank by 34.51% to $842721.0 in 2025, then declined by 3.19% to $815857.0 in 2026.
- Business Quant data shows NDRA's Total Non-Current Liabilities at $815857.0 in Q1 2026, $842721.0 in Q4 2025, and $992421.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 108.64 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 85.84 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 715.49 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 5.45 Bn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 22.94 Bn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 542.10 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 6.36 Bn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 3.39 Bn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 9.19 Bn |
| 10 | ENDRA Life Sciences | 7.16 Mn | 1.62 Mn | - | 845,936.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 845,936.00 |
| Mar 31, 2026 | 815,857.00 |
| Dec 31, 2025 | 842,721.00 |
| Sep 30, 2025 | 992,421.00 |
| Jun 30, 2025 | 757,884.00 |
| Mar 31, 2025 | 851,928.00 |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | 960,379.00 |
| Jun 30, 2024 | 98,421.00 |
| Mar 31, 2024 | 145,825.00 |
| Dec 31, 2023 | 192,062.00 |
| Sep 30, 2023 | 237,163.00 |
| Dec 31, 2022 | 365,919.00 |
| Mar 31, 2021 | 280,829.00 |
| Dec 31, 2020 | 608,992.00 |
| Sep 30, 2020 | 627,573.00 |
| Jun 30, 2020 | 645,450.00 |
| Mar 31, 2020 | 325,804.00 |
| Dec 31, 2019 | 342,812.00 |
| Sep 30, 2019 | 358,915.00 |